Tunisia Pharmaceuticals and Healthcare Report Q4 2017
BMI View: Tunisia's pharmaceutical market will continue to be met with challenges that ensuremultinational drugmakers remain wary of significant investment plans. A progressively improving businessclimate is having a notable impact on developments within the pharmaceutical sector and wider economy;however, the actual benefits will take time to materialise. Crucially, higher growth opportunities willpresent themselves within the generic medicines sector, while the high industry-associated risk profile willdeter any significant investment by multinational firms.
Headline Expenditure Projections
Pharmaceuticals: TND1.95bn (USD909mn) in 2016 to TND2.14bn (USD895mn) in 2017; +9.6%growth in local currency terms and -1.4% in US dollar terms.
Healthcare: TND6.5bn (USD3.0bn) in 2016 to TND6.9 (USD2.9bn) in 2017; +6.0% growth in localcurrency terms and -4.7% in US dollar terms.
Merck KGaA announced in July 2017 that it plans to roll out an innovative healthcare initiative inTunisia by 2019 - following its launch in Kenya in 2016.